Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Lymphoma, also known as malignant lymphoma, is a general term for a group of malignant tumors originating from the lymphopoietic system. It is one of the most common tumors in China. In 2020, there were 544,352 new cases of non-Hodgkin lymphoma (NHL) worldwide, ranking 13th among all new cases of malignancies.

Amoy Diagnostics, Premia Holdings, and Loxo Oncology recently announced a partnership aimed at genetic screening of patients for a targeted cancer therapy.

Almac Diagnostic Services recently announced that it has received CE marking for a next-generation sequencing-based diagnostic assay that will be used to determine molecular eligibility for enrolling patients in a pivotal Phase 2 portion of

Thermo Fisher Scientific recently announced a number of new partnerships in conjunction with the annual American Society for Mass Spectrometry Conference in Atlanta.

Horizon Therapeutics has partnered with Invitae for its urea cycle disorder genetic (UCD) testing program, through which individuals who may have the rare genetic condition and their family members will receive testing at no charge.

Quanterix announced after the close of the market on Wednesday that it has inked an agreement to acquire privately held UmanDiagnostics for $22.5 million.

Illumina has filed patent infringement suits in the US, Switzerland, and Turkey relating to BGI's sequencing instrumentation and chemistry, the company said today.

The global point of care (POC) diagnostics/testing market size is expected to grow at a CAGR of 3.3% over the forecast period 2019-2025 to reach USD 22.8 billion by 2025, driven by the ability of POC tests to render rapid and accurate resu

The US Food and Drug Administration has approved Qiagen's Therascreen PIK3CA RGQ PCR Kit as a companion diagnostic for identifying which advanced breast cancer patients have PIK3CA mutations and are likely to respond to Novartis' alpelisib (

Roche said recently that it has received US Food and Drug Administration 510(k) clearance for its Cobas TV/MG test for the detection of Trichomonas vaginalis (TV) and Mycoplasma genitalium (MG) DNA in symptomatic and asymptomatic patients.

PreludeDx said recently that the State of New York Clinical Laboratory Evaluation Program (CLEP) has approved its DCISionRT test, which assesses recurrence risk and can predict radiation therapy benefit in patients diagnosed with non-invasiv